GBT Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Global Blood Therapeutics (GBT) has announced participation in key investor conferences. Management will engage in virtual fireside chats at the William Blair Biotech Focus Conference on August 6, Wedbush PacGrow Healthcare Virtual Conference on August 11, and Canaccord Genuity 40th Annual Growth Virtual Conference on August 13. These events will be webcast live on GBT's website, with replays available for a month post-event. GBT focuses on developing treatments for sickle cell disease, including the FDA-approved Oxbryta and other drug candidates.

SOUTH SAN FRANCISCO, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:

• William Blair Biotech Focus Conference 2020 on August 6 at 3:00 p.m. ET;
   
• Wedbush PacGrow Healthcare Virtual Conference on August 11 at 2:55 p.m. ET; and
   
• Canaccord Genuity 40^th Annual Growth Virtual Conference on August 13 at 1:30 p.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcast will be archived and available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news. 

Contact Information:           
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Stephanie Yao (investors)
650-741-7730
syao@gbt.com

 

FAQ

What are the dates and times of GBT's upcoming investor conferences?

GBT will participate in the William Blair Biotech Focus Conference on August 6 at 3:00 p.m. ET, Wedbush PacGrow Healthcare Virtual Conference on August 11 at 2:55 p.m. ET, and Canaccord Genuity 40th Annual Growth Virtual Conference on August 13 at 1:30 p.m. ET.

Where can I watch the GBT fireside chats?

The fireside chats will be webcast live from GBT's website in the Investors section, with replays available for one month after the events.

What is the focus of Global Blood Therapeutics?

GBT is dedicated to the discovery and development of treatments for sickle cell disease, including their FDA-approved treatment Oxbryta.

What treatments are currently in development at GBT for sickle cell disease?

GBT is advancing its pipeline program with inclacumab, a p-selectin inhibitor aimed at addressing pain crises associated with sickle cell disease.

How does GBT aim to support underserved patient communities?

GBT is committed to delivering life-changing treatments for sickle cell disease, focusing on innovative therapies that address the needs of underserved patient communities.